Novavax (NVAX) stock soars 120% as Sanofi deal 'kicks off a new chapter'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
JPMorgan Upgrades Novavax (NVAX) to Neutral, 'Sanofi Licensing Deal Brings In Flu Heavy Weight and Lifts Going Concern'
May 10, 2024 9:27 AM EDTJPMorgan analyst Eric Joseph upgraded Novavax (NASDAQ: NVAX) from Underweight to Neutral.
The analyst comments "On the back of the announced licensing deal with Sanofi, we are upgrading Novavax shares to Neutral from Underweight. With the injection of cash upfront ($500M) removing Novavaxs going concern, , and the greater commercial heft brought to both COVID... More
Novavax (NVAX) Misses Q1 EPS by 13c; offers outlook
May 10, 2024 4:06 AM EDTNovavax (NASDAQ: NVAX) reported Q1 EPS of ($1.05), $0.13 worse than the analyst estimate of ($0.92). Revenue for the quarter came in at $93.85 million versus the consensus estimate of $141.16 million.
GUIDANCE:
Novavax sees FY2024 revenue of $800 million to $1 billion, versus the consensus of $845.5... More
